Stock listing
NASDAQ:NVCT Nuvectis Pharma, Inc. Stock
Home listing (NASDAQ) of Nuvectis Pharma, Inc.
Follow Nuvectis Pharma, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:NVCT
$19.39 USD -0.90 (-4.4%)
Close on Nov 20, 2026
- Day range
- $19.02 – $20.18 USDNov 20, 2026
- Volume
- 301,603 sharesNov 20, 2026
- Market cap
- $666.8M USDAt the close on Nov 20, 2026 · price × 34.39M shares outstanding
- 52-week range
- $5.77 – $29.28 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $4.39M USDMedian day 188,500 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:NVCT · Home | $19.39 USD | -0.90 (-4.4%) | 301,603 | $19.60 | $20.18 | $19.02 | $20.29 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:NVCT · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $19.39 | -0.90 | -4.4% | $19.60 | $20.18 | $19.02 | 301,603 | |
| $20.29 | +1.09 | +5.7% | $19.26 | $20.37 | $18.65 | 189,615 | |
| $19.20 | +0.09 | +0.5% | $19.09 | $19.92 | $18.75 | 181,014 | |
| $19.11 | -1.13 | -5.6% | $20.00 | $20.00 | $18.64 | 265,409 | |
| $20.24 | +0.01 | 0.0% | $20.17 | $20.38 | $19.60 | 208,983 | |
| $20.23 | -0.77 | -3.7% | $20.82 | $21.18 | $20.20 | 206,610 | |
| $21.00 | -0.08 | -0.4% | $21.31 | $21.78 | $20.61 | 153,122 | |
| $21.08 | +0.06 | +0.3% | $20.75 | $21.30 | $20.23 | 201,680 | |
| $21.02 | +0.11 | +0.5% | $21.09 | $22.18 | $19.72 | 385,116 | |
| $20.91 | +3.15 | +17.7% | $18.01 | $21.05 | $17.80 | 255,638 | |
| $17.76 | -0.71 | -3.8% | $18.15 | $18.53 | $17.24 | 340,097 | |
| $18.47 | -0.87 | -4.5% | $19.08 | $20.55 | $17.10 | 373,433 | |
| $19.34 | +0.16 | +0.8% | $19.18 | $19.69 | $18.82 | 143,079 | |
| $19.18 | +0.70 | +3.8% | $18.61 | $19.40 | $18.10 | 213,587 | |
| $18.48 | -0.09 | -0.5% | $18.46 | $18.92 | $18.20 | 168,802 | |
| $18.57 | +0.21 | +1.1% | $18.61 | $18.97 | $18.32 | 117,684 | |
| $18.36 | -0.08 | -0.4% | $18.30 | $18.83 | $17.91 | 192,736 | |
| $18.44 | -0.05 | -0.3% | $18.56 | $18.74 | $18.08 | 144,623 | |
| $18.49 | -1.56 | -7.8% | $20.00 | $20.41 | $17.69 | 318,829 | |
| $20.05 | -0.84 | -4.0% | $20.86 | $20.86 | $19.83 | 107,900 | |
| $20.89 | +0.19 | +0.9% | $20.55 | $21.26 | $20.40 | 110,100 | |
| $20.70 | +0.11 | +0.5% | $20.63 | $21.72 | $19.94 | 203,600 | |
| $20.59 | +1.65 | +8.7% | $19.09 | $20.91 | $17.85 | 148,800 | |
| $18.94 | +0.34 | +1.8% | $18.81 | $19.20 | $18.42 | 198,200 | |
| $18.60 | -0.33 | -1.7% | $18.89 | $18.89 | $17.81 | 158,500 | |
| $18.93 | +0.93 | +5.2% | $18.30 | $19.59 | $18.30 | 156,900 | |
| $18.00 | -0.15 | -0.8% | $18.27 | $18.72 | $17.68 | 184,200 | |
| $18.15 | -1.54 | -7.8% | $19.59 | $19.88 | $18.01 | 215,800 | |
| $19.69 | -1.43 | -6.8% | $21.12 | $21.19 | $19.55 | 145,800 | |
| $21.12 | +0.99 | +4.9% | $20.11 | $21.29 | $19.88 | 153,000 | |
| $20.13 | -0.16 | -0.8% | $20.05 | $20.42 | $19.60 | 179,400 | |
| $20.29 | +0.26 | +1.3% | $19.67 | $20.72 | $19.67 | 121,100 | |
| $20.03 | -1.36 | -6.4% | $21.54 | $21.54 | $19.79 | 188,100 | |
| $21.39 | -0.53 | -2.4% | $22.00 | $22.24 | $20.29 | 194,300 | |
| $21.92 | +1.20 | +5.8% | $21.11 | $22.00 | $21.04 | 207,500 | |
| $20.72 | -0.40 | -1.9% | $21.33 | $21.90 | $20.53 | 168,300 | |
| $21.12 | +0.59 | +2.9% | $20.73 | $21.62 | $20.41 | 240,300 | |
| $20.53 | -0.28 | -1.3% | $20.91 | $21.40 | $20.11 | 160,000 | |
| $20.81 | +0.59 | +2.9% | $20.00 | $21.24 | $19.55 | 137,900 | |
| $20.22 | -1.41 | -6.5% | $21.81 | $21.95 | $20.22 | 191,800 | |
| $21.63 | +0.56 | +2.7% | $21.38 | $21.99 | $20.65 | 258,200 | |
| $21.07 | -1.93 | -8.4% | $23.00 | $23.00 | $20.94 | 169,200 | |
| $23.00 | +1.02 | +4.6% | $22.26 | $23.18 | $21.79 | 124,000 | |
| $21.98 | -0.02 | -0.1% | $22.02 | $22.39 | $21.40 | 166,400 | |
| $22.00 | +0.62 | +2.9% | $21.27 | $23.00 | $21.06 | 880,100 | |
| $21.38 | -0.49 | -2.2% | $22.31 | $22.31 | $20.00 | 240,900 | |
| $21.87 | -0.05 | -0.2% | $21.84 | $22.41 | $21.31 | 136,400 | |
| $21.92 | -1.43 | -6.1% | $23.00 | $23.01 | $21.78 | 166,100 | |
| $23.35 | -0.64 | -2.7% | $23.25 | $24.12 | $22.79 | 203,400 | |
| $23.99 | +1.50 | +6.7% | $22.96 | $24.24 | $22.28 | 221,100 | |
| $22.49 | -0.29 | -1.3% | $22.09 | $23.02 | $22.01 | 107,000 | |
| $22.78 | -1.21 | -5.0% | $23.89 | $24.54 | $22.67 | 165,600 | |
| $23.99 | -0.50 | -2.0% | $24.00 | $24.69 | $22.73 | 136,300 | |
| $24.49 | +0.12 | +0.5% | $24.00 | $25.19 | $23.96 | 117,200 | |
| $24.37 | +0.45 | +1.9% | $24.00 | $24.62 | $22.82 | 136,000 | |
| $23.92 | +0.86 | +3.7% | $23.06 | $24.01 | $23.06 | 188,500 | |
| $23.06 | +0.33 | +1.5% | $22.80 | $23.81 | $22.77 | 176,900 | |
| $22.73 | -1.00 | -4.2% | $23.52 | $24.35 | $22.57 | 192,600 | |
| $23.73 | -1.46 | -5.8% | $24.93 | $25.65 | $23.29 | 137,200 | |
| $25.19 | +0.19 | +0.8% | $25.03 | $25.84 | $24.35 | 319,800 | |
| $25.00 | -0.89 | -3.4% | $25.80 | $25.80 | $23.84 | 362,900 | |
| $25.89 | +2.02 | +8.5% | $23.90 | $25.94 | $23.85 | 276,625 | |
| $23.87 | +0.31 | +1.3% | $23.56 | $24.55 | $23.34 | 231,128 | |
| $23.56 | +0.21 | +0.9% | $23.59 | $23.93 | $22.83 | 197,000 | |
| $23.35 | +0.02 | +0.1% | $22.98 | $23.99 | $22.36 | 230,000 |
- Ticker
- NASDAQ:NVCT
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 4, 2026
Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlights
Latest earnings call · Nov 4, 2026
Nuvectis Pharma (NASDAQ:NVCT) Q3 2026 Earnings Call
Replay and transcript
Latest deck · Nov 4, 2026
Q3 2026 Earnings Presentation
Earnings · 23 slides
Latest news
Nuvectis Pharma Reports Third Quarter 2026 Financial Results and Business Highlights
Nov 4, 2026
Closed $18.47 (-4.5%) on Nov 4, 2026
Nuvectis Pharma to Report Third Quarter 2026 Financial Results on November 4, 2026
Nov 2, 2026
Closed $19.34 (+0.8%) on Nov 3, 2026
Nuvectis Reports Positive Data from NXP200 Phase 1b Study Demonstrating Durable Responses, Including Complete Responses, in BRAF V600-mutated Recurrent or Progressive Gliomas
Oct 26, 2026
Closed $18.49 (-7.8%) on Oct 26, 2026
Nuvectis Pharma to Participate in the Maxim Growth Summit 2026
Oct 9, 2026
Closed $21.12 (+4.9%) on Oct 9, 2026
Nuvectis Announces NXP200 Granted Breakthrough Therapy Designation in China for BRAF V600-Mutant, Recurrent or Progressive, High-Grade Glioma
Sep 24, 2026
Closed $21.63 (+2.7%) on Sep 24, 2026
Nuvectis Pharma To Participate in Upcoming Investor Conferences
Sep 3, 2026
Closed $24.37 (+1.9%) on Sep 3, 2026
Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights
Aug 4, 2026
Closed $20.10 (-6.9%) on Aug 4, 2026
Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhibitors
Jul 23, 2026
Closed $20.15 (+4.5%) on Jul 23, 2026
Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock
Jun 29, 2026
Closed $18.39 (-35.5%) on Jun 30, 2026
Nuvectis Lands Major Haisco Deal for Two Potentially Best-in-Class Compounds in Multi-Billion-Dollar Markets
Jun 22, 2026
Closed $16.53 (+19.6%) on Jun 22, 2026
Nuvectis Pharma, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 17 in the last 12 months · 95 in all · newest Nov 4, 2026 · oldest 2022
- Calls
- 1 call with a replay · 1 with a transcript · latest Nov 4, 2026
- Decks
- 14 decks · latest Nov 4, 2026
Where Nuvectis Pharma, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:NVCT · Home listing · This page | NASDAQ | United States | USD |
| BOATS:NVCT | BOATS | United States | USD |
Valuation
Price/book 5.3× against a median of 4.2×: 9th lowest of 11 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $526.1M USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- No depreciation figure on 6ix yet
- Price/book
- 5.3×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.0×
- Beta vs S&P 500
- 0.84
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Nuvectis Pharma, Inc. · NASDAQ:NVCT | US$666.8M | US$526.1M | n/a | n/a | n/a | 5.3× | n/a | 0.0× | 0.84 |
| Attovia Therapeutics, Inc. · NASDAQ:ATTO | US$689.3M | US$297.2M | n/a | 220× | n/a | 1.7× | n/a | 0.0× | n/a |
| Lexicon Pharmaceuticals, Inc. · NASDAQ:LXRX | US$681.2M | US$549.9M | n/a | 14.3× | n/a | 4.2× | −161.8% | 0.3× | 1.15 |
| CARsgen Therapeutics Holdings Ltd. · HKEX:2171 | US$676.1M | US$477.2M | n/a | 25.4× | n/a | 4.1× | −77.9% | 0.1× | n/a |
| Philogen SpA · MIL:PHIL | US$672.3M | US$532.7M | 2.7× | 1.5× | n/a | 1.6× | 71.8% | 0.0× | n/a |
| Sun Pharma Advanced Research Co. Ltd. · NSE:SPARC | US$666.0M | US$519.1M | 3.8× | 2.5× | 2.9× | 4.3× | 84.7% | 0.0× | n/a |
| Oscotec Inc. · KRX:039200 | US$660.7M | US$660.7M | 11.6× | 6.3× | n/a | 4.5× | 54.0% | 0.0× | n/a |
| Shouyao Holdings Beijing Co. Ltd. Class A · SSE:688197 | US$647.3M | US$565.1M | n/a | 37.8× | n/a | 6.8× | −18.6% | 0.0× | n/a |
| Prime Medicine, Inc. · NASDAQ:PRME | US$645.8M | US$695.1M | n/a | 98.4× | n/a | 76.5× | n/a | 13.1× | 2.28 |
| Sagimet Biosciences Inc. - Series A · NASDAQ:SGMT | US$638.7M | US$404.3M | n/a | n/a | n/a | 2.6× | n/a | 0.0× | 1.96 |
| Gubra A/S · OMXCOP:GUBRA | US$638.5M | US$533.6M | 2.6× | 1.4× | 1.7× | 4.2× | 64.1% | 0.2× | n/a |
| Median of the others | US$663.4M | US$533.2M | 3.2× | 14.3× | 2.3× | 4.2× | 54.0% | 0.0× | 1.96 |
Forecasts
4 strong buy · 2 buy · Analysts' consensus from EODHD, read Nov 19, 2026. Not 6ix's view and not investment advice.
- Price target
- 35.40 USD · Analysts' mean
- EPS, year to Dec 2026
- -2.03 · 6 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| Ron Bentsur | Chairman, Chief Executive Officer and President |
| Enrique Poradosu | Executive Vice President, Chief Scientific and Business Officer |
| Shay Shemesh | Executive Vice President, Chief Development and Operations Officer |
Board
| Director | Role |
|---|---|
| Ron Bentsur | Chairman, Chief Executive Officer and President |
| James F. Oliviero | Director |
| Juan Sanchez | Director |
| Ken Hoberman | Director |
| Matthew L. Kaplan | Director |
Events
Calls
| Call | When | Status |
|---|---|---|
| Nuvectis Pharma (NASDAQ:NVCT) Q3 2026 Earnings Call | Wed, Nov 04, 2026 · 8:00 AM ET | Replay |
Results days
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 4, 2026 · Before open | −4.5% |
| Q2 2026 | Aug 4, 2026 · Before open | −6.9% |
| Q1 2026 | May 5, 2026 · Before open | +9.2% |
| Q4 2025 | Feb 11, 2026 · Before open | +0.5% |
| Q3 2025 | Nov 4, 2025 · Before open | −7.5% |
| Q2 2025 | Aug 5, 2025 · Before open | −5.3% |
| Q1 2025 | May 6, 2025 · Before open | −4.4% |
| Q4 2024 | Feb 25, 2025 | −6.8% |
| Q3 2024 | Nov 5, 2024 · Before open | +17.8% |
| Q2 2024 | Aug 6, 2024 · Before open | −5.8% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 7, 2024 · After close | −10.6% |
| Q4 2023 | Mar 5, 2024 · Before open | −1.0% |
| Q3 2023 | Nov 8, 2023 · Before open | −7.8% |
| Q2 2023 | Aug 9, 2023 · After close | +0.4% |
| Q1 2023 | May 10, 2023 · After close | +0.8% |
| Q4 2022 | Mar 7, 2023 · Before open | −4.7% |
| Q3 2022 | Nov 8, 2022 · Before open | +0.8% |
| Q2 2022 | Aug 10, 2022 · After close | +2.3% |
| Q1 2022 | May 12, 2022 · After close | +5.5% |
| Q4 2021 | Mar 22, 2022 · Before open | +14.4% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Q3 2026 Earnings Presentation | Earnings | 23 slides | Nov 4, 2026 |
| Investor Presentation (October 2026) | Investor deck | 24 slides | October 2026 |
| Investor Presentation (May 2026) | Investor deck | 27 slides | May 2026 |
| Investor Presentation (August 2025) | Investor deck | 26 slides | August 2025 |
| Investor Presentation (March 2025) | Investor deck | 27 slides | March 2025 |
| Investor Presentation (January 2025) | Investor deck | 27 slides | January 2025 |
| Investor Presentation (March 2024) | Investor deck | 25 slides | March 2024 |
| Investor Presentation (May 2023) | Investor deck | 24 slides | May 2023 |
| Investor Presentation (April 2023) | Investor deck | 23 slides | April 2023 |
| Investor Presentation (March 2023) | Investor deck | 23 slides | March 2023 |
All 14 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| Investor Presentation (November 2022) | Investor deck | 27 slides | November 2022 |
| IPO Roadshow (January 2022) | IPO roadshow | 22 slides | Jan 18, 2022 |
| IPO Roadshow (November 2021) | IPO roadshow | 25 slides | Nov 4, 2021 |
| IPO Roadshow (November 2021) | IPO roadshow | 24 slides | Nov 2, 2021 |
Financings
| Raise | Date |
|---|---|
| Public offering of shares (follow-on public offering) Closed: US$115M raised Use of proceeds: Advance development of NXP100 in PNH and other complement-mediated diseases and the oncology portfolio | Aug 4, 2026 |
| Public offering of common stock Update: US$100M · US$20 a share · Cantor +6 Dealers: Cantor (lead), H.C. Wainwright & Co., Laidlaw & Company (UK) Ltd., Lucid Capital Markets, Maxim Group LLC, Roth Capital Partners, Titan Partners, a division of American Capital Partners Use of proceeds: Advance NXP100, NXP200 and NXP900 programs, hiring, capital expenditures, public company costs and general corporate purposes | Jun 30, 2026 |
| At-the-market programme of shares Closed: at-the-market programme | Aug 5, 2025 |
| Public offering of common stock Closed: US$15.5M raised · US$5 a share · Lucid Capital Markets Dealers: Lucid Capital Markets (lead) Use of proceeds: Advance NXP800 and NXP900 development, hiring, capital expenditures, public company costs and general corporate purposes | Feb 7, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$5.00 a share on Feb 4, 2022.
- Price
- US$5.00 a share
- Shares offered
- 3,200,000 shares of common stock
- Offering size
- US$16 million
- Listing
- NVCT on the Nasdaq Capital Market
- Underwriter
- H.C. Wainwright & Co.
- Shares delivered
- On or about Feb 8, 2022
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jul 30, 2021 |
| Filed publicly | Oct 6, 2021 |
| Amended 6 times | Newest Jan 24, 2022 |
| Shares registered with an exchange | Feb 3, 2022 |
| Declared effective by the SEC | Feb 4, 2022 |
| Final prospectus, with the price | Feb 7, 2022 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Feb 7, 2022 |
| EFFECT · Notice that a registration is effective | Feb 4, 2022 |
| S-1MEF · Registration of more shares for the same offering | Feb 4, 2022 |
| CERT · Exchange's certificate of listing | Feb 4, 2022 |
| 8-A12B · Registration of shares for listing on an exchange | Feb 3, 2022 |
| CORRESP · Letter to the SEC | Feb 2, 2022 |
| CORRESP · Letter to the SEC | Feb 2, 2022 |
| S-1/A · Registration statement, amended | Jan 24, 2022 |
| FWP · Free writing prospectus | Jan 18, 2022 |
| S-1/A · Registration statement, amended | Jan 18, 2022 |
All 30 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Nov 30, 2021 |
| CORRESP · Letter to the SEC | Nov 30, 2021 |
| S-1/A · Registration statement, amended | Nov 30, 2021 |
| CORRESP · Letter to the SEC | Nov 26, 2021 |
| CORRESP · Letter to the SEC | Nov 26, 2021 |
| FWP · Free writing prospectus | Nov 9, 2021 |
| S-1/A · Registration statement, amended | Nov 8, 2021 |
| FWP · Free writing prospectus | Nov 4, 2021 |
| FWP · Free writing prospectus | Nov 2, 2021 |
| S-1/A · Registration statement, amended | Oct 28, 2021 |
| S-1/A · Registration statement, amended | Oct 21, 2021 |
| CORRESP · Letter to the SEC | Oct 20, 2021 |
| UPLOAD · Letter from the SEC | Oct 19, 2021 |
| CORRESP · Letter to the SEC | Oct 6, 2021 |
| S-1 · Registration statement | Oct 6, 2021 |
| UPLOAD · Letter from the SEC | Oct 1, 2021 |
| DRSLTR · Letter to the SEC with a draft | Sep 20, 2021 |
| DRS/A · Draft registration statement, amended | Sep 20, 2021 |
| UPLOAD · Letter from the SEC | Aug 26, 2021 |
| DRS · Draft registration statement | Jul 30, 2021 |
Open IPO · From the cover of the final prospectus (424B4) filed Feb 7, 2022
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 149.0K | 0 | |
| Cost of revenue | 22.9M | 19.2M | 12.9M | |||
| Gross profit | -22.9M | -19.1M | -12.9M | |||
| Research and development | 18.2M | 12.9M | 15.4M | 13.2M | 9.54M | |
| Selling, general and administrative | 9.42M | 6.93M | 7.52M | 6.01M | 3.35M | 24.0K |
| Operating income | -27.6M | -19.8M | -22.9M | -19.2M | -12.9M | -10.0K |
| Depreciation and amortization | 1.00M | 298.0K | 4.00K | 24.0K | ||
| EBITDA | -21.9M | -18.9M | -12.9M | 14.0K | ||
| Interest expense | 149.0K | 4.00K | 0 | |||
| Income before tax | -26.4M | -19.0M | -22.3M | -19.1M | -12.9M | -10.0K |
| Income tax | -19.0M | 1.00K | -298.0K | -4.00K | -24 | |
| Net income | -26.4M | -19.0M | -22.3M | -19.1M | -12.9M | -10.0K |
| Earnings per share, basic | -1.32 | -1.11 | -1.43 | -1.51 | -3.02 | -0.00 |
| Earnings per share, diluted | -1.32 | -1.11 | -1.43 | -1.51 | -3.02 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash and equivalents | 31.6M | 18.5M | 19.1M | 20.0M | 5.74M | 5.74M |
| Current assets | 31.7M | 18.6M | 19.2M | 20.4M | 5.83M | 5.83M |
| Total assets | 31.7M | 18.6M | 19.2M | 20.4M | 6.66M | 6.66M |
| Accounts payable | 6.27M | 2.50M | 2.77M | 2.91M | 1.06M | 10.0K |
| Current liabilities | 13.3M | 8.89M | 6.98M | 6.19M | 2.42M | 10.0K |
| Total liabilities | 13.3M | 8.89M | 6.98M | 6.19M | 2.42M | 10.0K |
| Shareholders' equity | 18.4M | 9.71M | 12.2M | 14.2M | -11.0M | -10.0K |
| Shares outstanding | 25.7M | 19.5M | 17.4M | 15.2M | 4.51M | 12.7M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|---|
| Cash from operations | -16.0M | -12.2M | -16.0M | -13.6M | -9.50M | 24.0K |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | -16.0M | -12.2M | -16.0M | -13.6M | -9.50M | 24.0K |
| Cash from investing | 0 | 0 | 0 | |||
| Cash from financing | 29.1M | 11.7M | 15.1M | 27.8M | 15.2M | 15.2M |
| Share buybacks | 27.8M | |||||
| Change in cash | 13.1M | -593.0K | -867.0K | 14.3M | 5.74M | 24.0K |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 10-Q · Quarterly report | Nov 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Nov 4, 2026 | Results | SEC |
| EFFECT · Notice that a registration is effective | Aug 31, 2026 | Other filings | SEC |
| S-3 · Registration statement | Aug 21, 2026 | Offer document | SEC |
| 8-K · Current report | Aug 21, 2026 | Current report | SEC |
| SCHEDULE 13G · Big-stake notice | Aug 6, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Aug 5, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Aug 4, 2026 | Quarterly report | SEC |
| 8-K · Current report | Aug 4, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Jul 1, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 30, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jun 30, 2026 | Offer document | SEC |
| 424B5 · Prospectus | Jun 29, 2026 | Offer document | SEC |
| 8-K · Current report | Jun 29, 2026 | Current report | SEC |
| 8-K · Current report | Jun 23, 2026 | Material contract | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 12, 2026 | Meeting outcome | SEC |
| 10-Q · Quarterly report | May 5, 2026 | Quarterly report | SEC |
| 8-K · Current report | May 5, 2026 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 27, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 27, 2026 | Meeting notice | SEC |
| EFFECT · Notice that a registration is effective | Feb 23, 2026 | Other filings | SEC |
| CORRESP · Letter to the SEC | Feb 18, 2026 | Other filings | SEC |
| UPLOAD · Letter from the SEC | Feb 18, 2026 | Other filings | SEC |
| S-3 · Registration statement | Feb 13, 2026 | Offer document | SEC |
| 8-K · Current report | Feb 11, 2026 | Results | SEC |
| 10-K · Annual report | Feb 11, 2026 | Annual report | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jan 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 6, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Nov 6, 2025 | Insider trade | SEC |
| 8-K · Current report | Nov 4, 2025 | Results | SEC |
| 10-Q · Quarterly report | Nov 4, 2025 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 31, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Oct 31, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Oct 29, 2025 | Insider trade | SEC |
| 8-K · Current report | Sep 25, 2025 | Management or board change | SEC |
| 10-Q · Quarterly report | Aug 5, 2025 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2025 | Results | SEC |
| 4 · Change in ownership | Jun 24, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2025 | Insider trade | SEC |
| 8-K · Current report | Jun 13, 2025 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jun 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2025 | Insider trade | SEC |
| 4/A · Change in ownership, amended | May 12, 2025 | Insider trade | SEC |
| 4 · Change in ownership | May 9, 2025 | Insider trade | SEC |
| 8-K · Current report | May 9, 2025 | Current report | SEC |
| 424B5 · Prospectus | May 9, 2025 | Offer document | SEC |
| 10-Q · Quarterly report | May 6, 2025 | Quarterly report | SEC |
| 8-K · Current report | May 6, 2025 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 28, 2025 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 28, 2025 | Meeting notice | SEC |
| 10-K · Annual report | Feb 25, 2025 | Annual report | SEC |
| 8-K · Current report | Feb 25, 2025 | Results | SEC |
| 4 · Change in ownership | Feb 11, 2025 | Insider trade | SEC |
| 424B5 · Prospectus | Feb 6, 2025 | Offer document | SEC |
| 8-K · Current report | Feb 5, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Feb 4, 2025 | Offer document | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Jan 3, 2025 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Jan 3, 2025 | Offer document | SEC |
| 4 · Change in ownership | Dec 26, 2024 | Insider trade | SEC |
| 4/A · Change in ownership, amended | Dec 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Dec 16, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 20, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Nov 8, 2024 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Nov 5, 2024 | Big-stake notice | SEC |
| 10-Q · Quarterly report | Nov 5, 2024 | Quarterly report | SEC |
| 8-K · Current report | Nov 5, 2024 | Results | SEC |
| 8-K · Current report | Aug 29, 2024 | Current report | SEC |
| 10-Q · Quarterly report | Aug 6, 2024 | Quarterly report | SEC |
| 8-K · Current report | Aug 6, 2024 | Results | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jun 13, 2024 | Insider trade | SEC |
| 8-K · Current report | Jun 13, 2024 | Meeting outcome | SEC |
| 4 · Change in ownership | May 15, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2024 | Insider trade | SEC |
| 4 · Change in ownership | May 13, 2024 | Insider trade | SEC |
| 10-Q · Quarterly report | May 7, 2024 | Quarterly report | SEC |
| 8-K · Current report | May 7, 2024 | Results | SEC |
| DEFA14A · Additional proxy material | Apr 29, 2024 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 29, 2024 | Meeting notice | SEC |
| 4 · Change in ownership | Mar 19, 2024 | Insider trade | SEC |
| 10-K · Annual report | Mar 5, 2024 | Annual report | SEC |
| 8-K · Current report | Mar 5, 2024 | Results | SEC |
| SC 13G/A · Big-stake notice, amended | Feb 28, 2024 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 6, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 31, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 31, 2024 | Big-stake notice | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 30, 2024 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 5, 2024 | Insider trade | SEC |
| 4 · Change in ownership | Jan 5, 2024 | Insider trade | SEC |
| 8-K · Current report | Nov 8, 2023 | Results | SEC |
| 10-Q · Quarterly report | Nov 8, 2023 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 10, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Oct 6, 2023 | Insider trade | SEC |
| 8-K · Current report | Sep 12, 2023 | Current report | SEC |
| 8-K · Current report | Aug 17, 2023 | Current report | SEC |
| 4 · Change in ownership | Aug 16, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Aug 11, 2023 | Insider trade | SEC |
| S-8 · Registration statement for employee plans | Aug 9, 2023 | Offer document | SEC |
| 8-K · Current report | Aug 9, 2023 | Results | SEC |
| 10-Q · Quarterly report | Aug 9, 2023 | Quarterly report | SEC |
| 4 · Change in ownership | Aug 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 31, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 28, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 27, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 24, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 24, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 19, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 18, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 13, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 12, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 10, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 7, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jul 6, 2023 | Insider trade | SEC |
| 8-K · Current report | Jul 3, 2023 | Results | SEC |
| 4 · Change in ownership | Jun 27, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 27, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 22, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 20, 2023 | Insider trade | SEC |
| 8-K · Current report | Jun 16, 2023 | Management or board change | SEC |
| 4 · Change in ownership | Jun 16, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 8, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jun 1, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 26, 2023 | Insider trade | SEC |
| 4 · Change in ownership | May 18, 2023 | Insider trade | SEC |
| 8-K · Current report | May 15, 2023 | Results | SEC |
| 10-Q · Quarterly report | May 10, 2023 | Quarterly report | SEC |
| 8-K · Current report | May 10, 2023 | Results | SEC |
| DEF 14A · Proxy statement | Apr 28, 2023 | Meeting notice | SEC |
| SC 13G · Big-stake notice | Apr 3, 2023 | Big-stake notice | SEC |
| EFFECT · Notice that a registration is effective | Mar 30, 2023 | Other filings | SEC |
| 4 · Change in ownership | Mar 28, 2023 | Insider trade | SEC |
| CORRESP · Letter to the SEC | Mar 27, 2023 | Other filings | SEC |
| 10-K/A · Annual report, amended | Mar 27, 2023 | Annual report | SEC |
| 4 · Change in ownership | Mar 27, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 23, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 22, 2023 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Mar 21, 2023 | Other filings | SEC |
| S-3 · Registration statement | Mar 17, 2023 | Offer document | SEC |
| 4 · Change in ownership | Mar 17, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Mar 16, 2023 | Insider trade | SEC |
| 10-K · Annual report | Mar 8, 2023 | Annual report | SEC |
| 8-K · Current report | Mar 7, 2023 | Results | SEC |
| SC 13G · Big-stake notice | Feb 13, 2023 | Big-stake notice | SEC |
| SC 13G · Big-stake notice | Feb 13, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Jan 13, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2023 | Insider trade | SEC |
| 4 · Change in ownership | Jan 13, 2023 | Insider trade | SEC |
| SC 13G/A · Big-stake notice, amended | Jan 9, 2023 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 22, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Nov 30, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Nov 29, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Nov 21, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Nov 18, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Nov 16, 2022 | Insider trade | SEC |
| 8-K · Current report | Nov 8, 2022 | Results | SEC |
| 10-Q · Quarterly report | Nov 8, 2022 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 3, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Sep 27, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Sep 27, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Sep 6, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Sep 6, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Sep 2, 2022 | Insider trade | SEC |
| 4 · Change in ownership | Aug 30, 2022 | Insider trade | SEC |
| EFFECT · Notice that a registration is effective | Aug 25, 2022 | Other filings | SEC |
| CORRESP · Letter to the SEC | Aug 23, 2022 | Other filings | SEC |
| 4 · Change in ownership | Aug 22, 2022 | Insider trade | SEC |
| UPLOAD · Letter from the SEC | Aug 19, 2022 | Other filings | SEC |
| 4 · Change in ownership | Aug 16, 2022 | Insider trade | SEC |
| S-1 · Registration statement | Aug 15, 2022 | Offer document | SEC |
| D | Aug 10, 2022 | Other filings | SEC |
| 10-Q · Quarterly report | Aug 10, 2022 | Quarterly report | SEC |
| 8-K · Current report | Aug 5, 2022 | Results | SEC |
| 8-K · Current report | Jul 29, 2022 | Material contract | SEC |
| 4 · Change in ownership | Jun 30, 2022 | Insider trade | SEC |
This page holds 200 of 275 filings. Open Filings
Cap table
Built by 6ix from Nuvectis Pharma, Inc.’s releases · as of Oct 30, 2026
- Common shares
- 34,388,908
- Fully diluted
- 34,388,908
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 34,388,908 | Oct 30, 2026 |
Share count over time
| Count | Shares |
|---|---|
| Oct 30, 2026 | 34,388,908 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Kenneth Hoberman Other companies: TG Therapeutics, Inc. (Chief Operating Officer and Corporate Secretary · Since at least Jun 26, 2018); Stemline Therapeutics Inc (Chief Operating Officer · Dec 15, 2017 – Jun 10, 2020 · Past) | Director · Since at least Feb 8, 2022 |
| Ron Bentsur Other companies: Beyond Air, Inc. (Director · Jul 27, 2020 – Nov 22, 2024 · Past); Stemline Therapeutics Inc (Director · Jun 25, 2019 – Jun 10, 2020 · Past) | Chairman & CEO, Director · Since at least Feb 4, 2022 |
| James F Oliviero III Other companies: Checkpoint Therapeutics Inc (CEO, President and Director, Director · Since at least Apr 2, 2025) | Director · Since at least Jun 12, 2025 |
| Uri Ben-or Other companies: Scinai Immunotherapeutics Ltd. (Director · Since at least Jan 1, 2023) | Int. Principal Financial Off. · Feb 8, 2022 – Feb 8, 2022 · Past |
| Enrique Poradosu | Executive Vice President, Chief Scientific and Business Officer · Since at least Jan 3, 2024 |
| James F. Oliviero | Director · Since at least Jun 12, 2026 |
| Juan Sanchez | Director · Since at least Sep 22, 2025 |
| Ken Hoberman | Director · Since at least Jun 12, 2026 |
| Matthew L. Kaplan | Director · Since at least Feb 8, 2022 |
| Michael J Carson | Vice President, Finance · Since at least Mar 18, 2022 |
All 12 people
| Person | Seat |
|---|---|
| Ron Bentsur | Chairman, Chief Executive Officer and President · Since at least Jul 1, 2026 |
| Shay Shemesh | Chief Dev. & Ops. Officer · Since at least Jan 6, 2026 |
Log in to ask 6ix AI your own questions about Nuvectis Pharma, Inc.